The 7th Annual Breast Cancer Update:
Screening, Diagnosis and Current Treatment
Friday, November 6, 2009
Marriott Waterfront Hotel
Continuing Medical Education Information
CME Sponsorship
This educational activity is sponsored by the University of Maryland School of Medicine.
Overview
Breast cancer is the most common cancer among women in the United States, with an estimated
180,000 new cases diagnoses annually. A multi-disciplinary focus that entails prevention,
diagnosis, and treatment has led to significant strides in the reduction of breast cancer incidence
and mortality. Additionally, breast cancer management has become increasingly complex,
requiring comprehensive assessment and review of multiple issues that include the role of genetic
testing, imaging and breast magnetic resonance imaging, surgical and reconstructive options, and
a variety of new adjuvant therapies.
Target Audience
This educational activity is intended for physicians and allied health care personnel, including
primary care physicians, general surgeons, medical oncologists, radiation oncologists,
radiologists, nurse practitioners with an interest on the multi-disciplinary approach to diagnosis
and treatment of breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to describe and discuss:
 The comprehensive multidisciplinary approach to the evaluation and treatment of breast
cancer patients.
 Treatment recommendations for stages 1-3 of breast cancer.
 Recommendations for genetic evaluation and testing.
 Screening methods for breast cancer, including the role of MRI and ultrasound.
 Implications of positive / abnormal mammograms.
 New surgical techniques in breast reconstruction.
 Programs and resources for breast cancer survivorship and support.
Accreditation
The University of Maryland School of Medicine is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The University of Maryland School of Medicine designates this educational activity for a
maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should only claim credit
commensurate with the extent of their participation in the activity.
Disclosure
It is the policy of the University of Maryland School of Medicine to ensure balance,
independence, objectivity, and scientific rigor in all of its educational activities. In accordance
with this policy, all persons in a position to control activity content of continuing medical
education activities must disclose their financial relationships with commercial interests relevant
to the content of the CME activity. Any conflicts of interest identified must be resolved prior to
presentation of the educational activity.
1
The following individuals have disclosed no relevant financial relationships with commercial
interests:





Ting Bao, M.D., DABMA
Robert R. Buras, M.D., F.A.C.S.
Cristina Campassi, M.D.
Saranya Chumsri, M.D.
Anil A. Dhople, M.D.





Amy M. Fulton, Ph.D.
Olga B. Ioffe, M.D.
Eduardo D. Rodriguez, M.D., D.D.S.
Jessica E. Rispoli Joines, M.G.C., C.G.C.
Katherine H. Rak Tkaczuk, M.D.
Discussion of Off-Label or Investigational Uses
Presentations in this continuing medical education activity may contain references to unlabeled or
unapproved uses of drugs or devices. The audience is advised to consult the full prescribing
information of all drugs or devices prior to use. Some drugs/devices identified during this activity
may have United States Food and Drug Administration (FDA) clearance for specific purposes
only or for use in restricted research settings. The FDA has stated that it is the responsibility of
the individual physician to determine the FDA status of each drug or device that he/she wishes to
use in clinical practice and to use the products in compliance with the applicable law.
UMSOM requires that all contributors disclose any unlabeled use or investigational use (not yet
approved for any purpose) of pharmaceutical and medical device products and provide adequate
scientific and clinical justification for such use. Physicians are urged to fully review all the
available data on products or procedures before using them to treat patients.
Disclaimer
This CME activity is designed for use by healthcare professionals for educational purposes only.
Information and opinions offered by the contributors represent their viewpoints. Conclusions
drawn by the participant should be derived from careful consideration of all available scientific
information. Prescription information and use of medical devices should be undertaken only after
confirmation of information by consulting the FDA-approved uses and information.
While UMSOM makes every effort to have accurate information presented, no warranty,
expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge,
experience, and diagnostic decision-making before applying any information, whether provided
here or by others.
Acknowledgement of Support
The following institutions, organizations, and/or companies have provided educational grants in
support of the 7th Annual Breast Cancer Update:
Genentech
2